Sep 2024
2024-2025 RSV Prevention Program for infants in Ontario
Introduction
Respiratory Syncytial Virus (RSV) is a major cause of illness among infants and young children. Among children under two, there were 3,850 hospitalizations during the 2022-2023 RSV season. Ontario’s RSV Prevention Program for infants is changing and expanding to provide more protection to infants during the 2024-2025 RSV season and to reduce impact on system capacity.
This resource is designed to help primary care clinicians navigate the new RSV Prevention Program for infants and high-risk children by providing them with information and supports to promote RSV prevention among their patients, answer patient questions, and implement Beyfortus (Nirsevimab) administration in their practice.
Share resource
Information
About the tool
This resource supports primary care clinicians with different aspects of RSV prevention for infants and high-risk children in Ontario. The resource provides a focus on:
- Ontario’s RSV Prevention Program for infants and high-risk children in 2024-2025
- The Beyfortus (Nirsevimab) product and its administration
- Primary care’s role in RSV prevention for infants and high-risk children
This resource was created with information from and in collaboration with the Chief Medical Officer of Health. End users and expert reviewers were also engaged throughout the resource development process (e.g., usability testing sessions) to provide feedback and support the resource’s refinement.
The tool is among several clinical tools developed as part of the Knowledge Translation in Primary Care Initiative. Funded by the Ministry of Health, this initiative supports primary care providers with the development of a series of clinical tools and health information resources. Learn more about the Knowledge Translation in Primary Care Initiative (KTinPC).